Why Pharma Products still go to Waste and How Better Logistics can Help
Next-generation Water Systems in Pharma
Microbiological QC Bottlenecks in Biopharma
Breaking Barriers in bioanalytical automation
TRADITIONAL PHARMA FACILITIES
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Datamonitor
Analyst
include the changing patent laws as countries aim to become more TRIPS compliant with India updating its law recently and China in the process of doing so through the WTO Increasing globalization of the generics market with Indian companies becoming involved in Europe and the US and vice versa will also provide an opportunity for generics companies
Articles
The Unknown Sources of Error in the Pharmaceutical Weighing Process
PROCESS WEIGHING AND RECORDING BY OBSERVATION This is the process flow for weighing the reference standard where the values are recorded by observation from the balance screen and written into a laboratory notebook by an analyst The subsequent calculations are performed using a handheld calculator with the res
Research Insights
New Agents For The Treatment Of Drug-resistant Mycobacterium Tuberculosis
Abstract Inadequate dosing and incomplete treatment regimens coupled with the ability of the tuberculosis bacilli to cause latent infections that are tolerant of currently used drugs have fueled the rise of multidrugresistant tuberculosis MDRTB Treatment of MDRTB infections is a major clinical challenge that has few viable or effective solutions theref
Case Studies
High Concentration Antibody - Rituximab
Challenge Antibodies tend to aggregate at the high concentrations typically required for their therapeutic application The key challenge of this study was to reduce the rate of aggregation in isotonic aqueous formulation of rituximab at mgml whilst maintai
Techno Trends
Evotec and Eternygen to Develop Novel Metabolic Disease Therapy
Evotec and Eternygen announced a drug discovery collaboration to develop novel metabolic disease therapy The two companies will develop novel small molecule inhibitors against an Eternygen target to treat metabolic disease using Evotecs technology platform and broad expertise in drug discovery and preclinical development Eternygen is working on the sodium couple...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Determinants of Antimicrobial Resistance (AMR) Research in South East Asia
Raja Chakraverty is a serving Scientist with the Indian Council of Medical Research with a decade long research and teaching career in Pharmaceutical Sciences with 54 publications (186 citations) and a book
Doctoral Scholar, Department of Pharmaceutical Technology
Quercetin - A Super Food For Therapeutic Interventions
Mohini Sikarwar is a PhD Scholar at Centre for Development of Biomaterials, Sharda University, Greater Noida, India. Her research is focusing on advanced drug delivery systems with a commitment to enhancing therapeutic efficacy of poorly water-soluble drug for Leishmaniasis treatment. She is aiming to revolutionise the current treatment methods of Kala azar using drug delivery approaches.
Dr. Piyush Kumar Gupta is currently head of the Centre for Development of Biomaterials at Sharda University, Greater Noida, India. His area of expertise belongs to Biomaterials, Pharmaceutics, and Nanotoxicology. He has published 143 SCIE and Scopus-indexed peer-reviewed articles and 7 book chapters in his area of expertise. He has been bestowed with several International or National awards.
Artificial Intelligence - A current and future tool to learn chemical sciences
Ruchi Bharti received her M.Sc. from Patna University, in organic chemistry. PhD from National Institute of Technology Patna (NIT Patna), in 2012. There she worked on the development of new organocatalysts and their utilization in the synthesis of diverse heterocyclic compounds via multimulticomponent reactions. In 2017, she enrolled as assistant professor at R. P Sharma Institute of Technology, Since 2018, she joined Department of Chemistry, University Institute of Sciences, Chandigarh University, Punjab as Assistant Professor. Her recent research work is focused on the functionalisation of diverse heterocycles, multicomponent reactions, organocatalysis and their related biological and medicinal applications.
3D Printing
Stéphane Roulon is a pharmaceutical entrepreneur with over ten years of experience in developing 3D printing technologies for drug manufacturing. He is the CEO of MB Therapeutics, a pharmaceutical establishment specializing in personalized medicines produced using advanced 3D printing solutions to support the future of precision medicine.
Why tier-2 and tier-3 cities are not included for clinical research
Co-Founder at DPHS Pvt. Ltd., Dr. Krutikesh Age is a researcher and a visionary committed towards propelling the field of clinical research and healthcare expansion in India. As the Co-founder of DPHS, Krutikesh manages varied key roles including Leadership, developing business and marketing strategies and Networking to name a few. It is through the deep understanding of clinical research and market dynamics that he has been instrumental in expanding the operations of DPHS in the past few years.
press releasesRead more...
Agilent and Singapore’s NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research
Agilent Technologies Inc today announced a twoyear research collaboration agreement with Singapores Nucleic Acid Therapeutics Initiative NATi hosted by Agency for Science Technology and Research ASTAR to accelerate research
Samsung Bioepis Launches Ustekinumab Biosimilar, Marking Its First Product Launch in Japan
Samsung Bioepis Co Ltd today announced the launch of Ustekinumab BS mg Syringe for SC Injection NIPRO a biosimilar referencing Stelara ustekinumab marking its first product launch in Japan under partnership
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
QIAGEN announced at the BIOIT World Conference Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
Incyte NasdaqINCY and Edison Scientific today announced a strategic collaboration to employ Kosmos Edisons AI scientist for Incytes discovery and development work
Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy
Amplexd Therapeutics Inc Amplexd a USbased clinicalstage biotechnology company focused on womens health and underserved therapeutic areas today announced authorization from the Hong Kong Department
Bridging Global Markets: Cathay Cargo Redefines Cold Chain Excellence via Hong Kong’s Strategic Nexus
In the rapidly evolving logistics landscape of precision and speed define the ultimate prerequisites for highvalue essentials Leveraging Hong Kongs unparalleled geographical superpower
EventsRead more...
20 - 21
May 2026Pharmacovigilance Europe 2026
London, UK
20 - 21
May 2026Pharma Partnering EU Summit 2026
Pharma Partnering Summit
Basel Marriott Hotel, Switzerland
20 - 22
May 2026PHARMA EURASIA 2026
Pharma & Med Tech Park, Tashkent, Uzbekistan
21 - 22
May 2026Liver Diseases & Hepatology 2026
Paris, France
27 - 28
May 2026Digi-Tech Pharma & AI Conference
London, United Kingdom
27 - 28
May 2026Global Clinical Trials Connect 2026
London, United Kingdom
27 - 28
May 2026UK Biotech Day
Radisson Hotel & Conference Centre London Heathrow, UK
27 - 28
May 2026Future Labs Live 2026
Congress Center, Basel, Switzerland
LATEST NEWSRead more...
Exelixis and Merck Collaborate on Phase 3 Trial for Colorectal Cancer Treatment
Exelixis has announced a clinical development collaboration with Merck for the Phase STELLAR pivotal trial in patients with colorectal cancer CRC
AstraZeneca and Daiichi Sankyo Expand ENHERTU Use in Early HER2-Positive Breast Cancer in the US
AstraZeneca and Daiichi Sankyo have received approval from the US Food and Drug Administration for the use of Enhertu trastuzumab deruxtecan in both neoadjuvant and adjuvant treatment settings for patients with HERpositive early breast cancer
Regeneron and Parabilis Partner to Develop Antibody-Helicon Conjugates Across Multiple Therapeutic Areas
Regeneron Pharmaceuticals has announced a strategic research collaboration with Parabilis Medicines to discover and develop therapeutic candidates using Parabilis Helicon peptide platform
Elabscience Launches PolyHRP-Streptavidin Conjugate for ELISA Testing
Elabscience has launched a selfdeveloped PolyHRPStreptavidin conjugate designed to improve the sensitivity of enzymelinked immunosorbent assay ELISA testing for lowabundance biomarker detection
Erasca Enters into Collaboration with Merck to Evaluate ERAS-0015 with KEYTRUDA in RAS-Mutant Solid Tumours
Erasca has entered into a clinical trial collaboration and supply agreement with Merck to evaluate ERAS in combination with KEYTRUDA for patients with RASmutant solid tumours
Hengrui Pharma Enters into Collaboration with Bristol Myers Squibb to Advance Innovative Therapies
Hengrui Pharma and Bristol Myers Squibb have entered into global strategic collaboration and licensing agreements to develop a portfolio of earlystage programmes across oncology haematology and immunology
